can kill man, but there is salvation, it is already being developed by scientists from the gamaleya research centerhe latest anti-oven. against batuulism, its development cost tens of millions of rubles, but the drug cannot be administered to patients yet, the fact is that the antidote is at the stage clinical trials, first it needs to be tested on animals, then on healthy volunteers, only after passing all stages, the medicine will be available for widespread use. the active substance is a monoconal antibody that specifically binds to the toxin and blocks its penetration into the cell. now he treats seriously ill patients with batulism. already existing serum made from the blood of horses, but the drug is not a panacea, if you delay, it will not save a new effective antidote should arrive in hospitals already in next year. alena skachkov, stanislav ponomarenko, vasily yurchuk, dinara yusipova, lead the duty department. the outgoing week turned out to be very busy for the head of the russian ministry of internal affairs, vladimir kolokoltsev. it started with a work trip. in uzbekistan in tashkent ,

scientists from several research centers are working on the drug, blakhina, hercyn and gamaleya.usual sense, it is not intended for healthy people, it is a therapeutic vaccine for those who already have cancer. why is it called a vaccine, because it forces the body to develop immunity and fight the tumor itself, this is not preventive from the point of view of the classic infectious vaccine therapy approach, yes, that is, we cannot immunize him while a person is sick, but after that, how did we get the tumor sample, this vaccine can be used against relapses, against metastases, which can occur, if you don’t go into scientific terminology... the mechanism of action of the vaccine is simple, similar to the principle of immunotherapy: after a patient with cancer is operated on, a piece of the tumor is sent to the laboratory and studied with the help of all possible modern diagnostics. we have a developed bioinformation system that allows us to obtain data on specifically individual markers of a given patient from the genetic material of a patient’s normal tumor. tumors. based on the